{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-326083","form_type":"8-K","ticker":"TEM","cik":"0001717115","company_name":"Tempus AI, Inc.","filed_at":"2026-07-30T20:01:15+00:00","discovered_at":"2026-07-30T20:02:00.492079+00:00","generated_at":"2026-07-30T20:02:16.393004+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tempus AI Q2 revenue $382.5M (+22% YoY); raises FY2026 guidance to $1.595-1.605B","bullets":["Revenue $382.5M, up 22% YoY; GAAP net income $5.6M vs loss $42.8M in Q2 2025.","Adjusted EBITDA $8.0M vs -$5.6M; FY2026 revenue guidance raised to $1.595-1.605B.","Signed ~$200M in new Data and Applications licenses; MRD volume 9,000 tests.","Agreed to acquire Personalis for $16.25/share (~$1.5B enterprise value).","FDA approved xT Tumor Only CDx assay; first lab with both tumor-only and tumor-normal CDx."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-326083","json":"https://secwatch.observer/filing/0001193125-26-326083.json","markdown":"https://secwatch.observer/filing/0001193125-26-326083.md","text":"https://secwatch.observer/filing/0001193125-26-326083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1717115/000119312526326083/0001193125-26-326083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1717115/000119312526326083/tem-20260730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T20:02:16.393004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}